Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3429 | SARS-CoV-2 convalescent plasma Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007410 | Intestinal Diseases NIH | 0.50 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.33 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002242 | Abnormal intestine morphology HPO | 0.50 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.33 |
Navigate: Correlations HPO
There is one clinical trial.
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
Description: Cumulative incidence measured as the proportion of subjects who were hospitalized or who died prior to hospitalization
Measure: Cumulative incidence of hospitalization or death prior to hospitalization Time: Up to day 28Description: Cumulative incidence of treatment-related serious adverse events categorized separately as either severe infusion reactions or Acute Respiratory Distress Syndrome (ARDS) during the study period.
Measure: Cumulative incidence of treatment-related serious adverse events Time: Up to day 28Description: Cumulative incidence measured as the proportion of subjects experiencing a Grade 3 or higher.
Measure: Cumulative incidence of treatment-related grade 3 or higher adverse events Time: Up to day 90Description: Analysis of serum SARS-CoV-2 antibody titers will also primarily be descriptive, comparing the geometric mean titers at day 0, 14, 28 and 90 between the randomized arms and calculating the shift or change in the titer distribution.
Measure: Change in serum SARS-CoV-2 antibody titers Time: Days 0, 14, 28 and 90Description: Compare the rates and duration of SARS-CoV-2 RNA positivity (by RT-PCR) of nasopharyngeal or oropharyngeal fluid between active and control groups at days 0, 14 and 28
Measure: Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity Time: Day 0, 14 and 28Description: Compare the levels of SARS-CoV-2 RNA between active and control groups at days 0, 14 and 28
Measure: Change in level of SARS-CoV-2 RNA Time: Day 0, 14 and 28Description: Comparison of participant self-assessed blood oxygen saturation levels (in percentage oxygen) between treatment arms using pulse oximetry from Day 0 to Day 28.
Measure: Change in oxygen saturation levels Time: Day 0 to Day 28 (where available)Description: Secondary infection will be assessed by measuring the number of individuals that live in the same house as the active arm who became sick by the end of follow-up period.
Measure: Rate of participant-reported secondary infection of housemates Time: Up to day 90Description: Disease severity measured by time (in days) to admission to the ICU or , invasive mechanical ventilation or time to death.
Measure: Time to ICU admission, invasive mechanical ventilation or death in hospital Time: Up to day 90Description: Time (in days) to resolution of COVID-19 symptoms will be based on temperature logs and symptom score sheets.
Measure: Time to resolution of COVID-19 symptoms Time: Up to day 90Description: Assess change in hospitalization rate as measured by number of hospitalizations stratified by age groups <65 and >=65
Measure: Impact of convalescent plasma on outcome as assessed by change in hospitalization rate Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by hospitalization rate as measured by number of hospitalizations.
Measure: Impact of donor antibody titers on hospitalizaton rate of convalescent plasma recipients Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by antibody levels
Measure: Impact of donor antibody titers on antibody levels of convalescent plasma recipients Time: Day 0 to Day 90Description: Impact of donor antibody titers (high/low) will be assessed by viral positivity rates (number of SARS-CoV-2 positive cases per total cases)
Measure: Impact of donor antibody titers on viral positivity rates of convalescent plasma recipients Time: Day 0 to Day 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports